Strong R&D Focus CureVac has over 25 years of research expertise with nearly 1,000 mRNA patents, emphasizing its robust innovation pipeline and intellectual property strength, which positions it as a key partner for collaborations in cutting-edge mRNA therapeutic projects.

Expanding Clinical Portfolio The company has secured regulatory clearance from the European Medicines Agency for multiple cancer immunotherapy candidates and is progressing with Phase 1 trials, presenting opportunities for partnerships in oncology and personalized medicine markets.

Significant Funding & Revenue Potential With a strong cash position of approximately €416 million and revenue between $50 million and $100 million, CureVac offers a financially stable platform to support large-scale research collaborations and innovative product development initiatives.

Strategic Acquisitions and Alliances Recent involvement in BioNTech's acquisition process and resolution of patent litigations highlight potential for joint ventures and licensing agreements in mRNA technology, appealing to partners seeking to expand their mRNA portfolio.

Market Position & Competitiveness As a leading biotech focused on mRNA applications with strategic regulatory and corporate developments, CureVac is well-positioned to collaborate with global pharmaceutical companies seeking to enhance their mRNA-based offerings and accelerate market entry.